AstraZeneca

AZNleader

AstraZeneca is a global biopharmaceutical company with a market-leading oncology portfolio and strong positions in cardiovascular, respiratory, and rare disease therapies.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($49.8B)

Datos estáticos (cargando finanzas en tiempo real…)

Oncology (40%)

BioPharmaceuticals (38%)

Rare Disease (Alexion) (17%)

Other (5%)

Composición de segmentos y clientes principales

Detalles del producto

Oncology Portfolio40%

Tagrisso, Imfinzi, Enhertu, and Lynparza cancer treatments

Cardiovascular/Renal/Metabolic22%

Farxiga, Brilinta, and Lokelma for heart and kidney disease

Respiratory & Immunology20%

Symbicort, Fasenra, and Tezspire for asthma and COPD

Rare Disease (Alexion)18%

Soliris, Ultomiris for complement-mediated diseases

Relaciones en la Cadena de Suministro

Competidores

Merck & Co.

Oncology immunotherapy

Impacto: High — PD-L1 vs PD-1 competition

Pfizer Inc.

Respiratory and oncology

Impacto: Medium — multiple overlapping areas

Socios

Eli Lilly and Company

Enhertu co-development (with Daiichi Sankyo)

Impacto: N/A — Daiichi partner, Lilly rival

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de AstraZeneca impulsado por IA.

Información de la Empresa

Sede Central

Cambridge, United Kingdom

Fundación

1999

Empleados

89,000+

Sitio Web

astrazeneca.com

Estado del sector — 제약 / 바이오

Noticias del sector